<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02602210</url>
  </required_header>
  <id_info>
    <org_study_id>SCOTCH-SCotCHIS in the UK</org_study_id>
    <nct_id>NCT02602210</nct_id>
  </id_info>
  <brief_title>Supplemental Corticosteroids in Cirrhotic Hypotensive Patients With Suspicion of Sepsis</brief_title>
  <acronym>SCOTCH;</acronym>
  <official_title>Supplemental Corticosteroids in Cirrhotic Hypotensive Patients With Suspicion of Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of the study is to investigate the clinical relevance, efficacy and safety of
      treating hypotensive cirrhotic patients with suspicion of sepsis and on vasopressors with
      low-dose hydrocortisone in order to reverse hemodynamic instability and organ failure and to
      decrease mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ample evidence suggests that a significant number of patients (52-77%) with chronic liver
      disease develop adrenal insufficiency in case of concomitant sepsis. This condition impairs
      hemodynamic integrity and probably worsens often encountered multiorgan failure. Different
      groups suggested that treating those patients with corticosteroids gives a faster reversal of
      hemodynamic instability and even lowers mortality compared to historical controls. However,
      most of the published data are retrospective and comprise small groups of patients. These
      data raise the possibility that corticosteroids at stress doses may be beneficial in
      hypotensive cirrhotics admitted to the ICU but as yet this has not been subjected to a
      large-scale multicentre randomized controlled clinical trial.

      The study will be a double-blind, randomized, placebo-controlled, multicenter trial,
      involving tertiary intensive care units with expertise in management of patients with
      decompensated cirrhosis. Patients who satisfy inclusion criteria and do not present any of
      the exclusion criteria at ICU admission will be randomized into two groups:

        -  Group A: treated with intravenous hydrocortisone in addition to standard therapy (=
           treatment group)

        -  Group B: placebo (NaCl 0.9%) treatment in addition to standard treatment (= placebo
           group)

      If, after adequate fluid resuscitation, patients are still on norepinephrine at a dose of at
      least 0,1 mcg/kg/min for at least 4 hours, the patient can be randomized. Study drug can be
      started immediately after randomization but no later than 24 h after initiation of
      norepinephrine. Patients will receive an intravenous bolus of 50 ml of normal saline
      (placebo) or an intravenous bolus of 50 ml of normal saline containing 100 mg of
      hydrocortisone (double-blind) that will be followed by a continuous intravenous infusion of
      the study drug (hydrocortisone) or placebo. Treatment with study drug (hydrocortisone or
      placebo) at initial rate will be maintained until the start of day 4 and gradually
      discontinued (reduction of infusion rate with 0.5 ml/h/d) when 1) patients do not require
      vasoactive drugs anymore to maintain MAP(mean arterial pressure) &gt; 60 mmHg or &gt; 65 mmHg if
      associated with signs of hypoperfusion in spite of ongoing adequate fluid resuscitation or 2)
      in any case after a 7-day treatment period.

      Investigators, treating physicians, nurses and patients will be blinded to the intervention.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient survival at 28 days analysed from the day of randomisation</measure>
    <time_frame>28days</time_frame>
    <description>survival status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>patient survival at 90 days analysed from the day of randomization</measure>
    <time_frame>90 days</time_frame>
    <description>survival status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU and hospital mortality</measure>
    <time_frame>from the date of randomisation until ICU discharge or hospital mortality, whichever came first, up to day 90</time_frame>
    <description>mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reversal of shock</measure>
    <time_frame>up to day 90</time_frame>
    <description>time in days from start of placebo or active medication to resolution of shock as defined as cessation of continuous vasopressor medication (for &gt; 24 hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reversal of organ failures</measure>
    <time_frame>up to 90 days</time_frame>
    <description>measured with SOFA-score and CLIF (Chronic Liver Failure Consortium)-SOFA score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vasopressor doses</measure>
    <time_frame>up to 90 days</time_frame>
    <description>administration of vasopressor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vasopressor-free days</measure>
    <time_frame>up to 90 days</time_frame>
    <description>days without vasopression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mechanical ventilation-free days</measure>
    <time_frame>up to 90 days</time_frame>
    <description>days without mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for and duration of renal replacement therapy</measure>
    <time_frame>up to 90 days</time_frame>
    <description>days of renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU and hospital length-of-stay</measure>
    <time_frame>up to 90 days</time_frame>
    <description>days of ICU stay , days of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acquirement of new infections</measure>
    <time_frame>up to 90 days</time_frame>
    <description>bacterial and/or fungal: defined according to CDC (Centers for Diseases Control) criteria (pneumonia, bacteremia, spontaneous bacterial peritonitis, catheter-related bloodstream infections, skin infections and others)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>shock relapse</measure>
    <time_frame>during tapering period until 3 days after end of study drug</time_frame>
    <description>defined as hypotension recurrence during the tapering period or within 3 days of total discontinuation of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinically important bleeding</measure>
    <time_frame>up to 90 days</time_frame>
    <description>defined as new melena, new haematemesis or unexplained fall in haemoglobin &gt; 2g/dl (not related to volume expansion). The presence of 'coffee ground' aspirate from nasogastric aspirate will not be considered active GI bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glycemic control</measure>
    <time_frame>during ICU stay, up to 10 days</time_frame>
    <description>measured as units of insulin required to attain glycemic levels between 80 - 140 mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>episode of hyper- (&gt; 180 mg/dl) or hypoglycemia (&lt; 60 mg/dl)</measure>
    <time_frame>during study treatment period, up to 10 days</time_frame>
    <description>number of episodes of hypo- hyperglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>new shock episode</measure>
    <time_frame>during study treatment period, up to 13 days</time_frame>
    <description>hypotension recurrence with need for vasopressor therapy after 3 days of total discontinuation of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>impact of coagulopathy</measure>
    <time_frame>during ICU stay up to 10 days</time_frame>
    <description>assessed by disseminated intravascular coagulopathy (DIC)-score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of ICU-acquired weakness</measure>
    <time_frame>during ICU stay, up to 90 days</time_frame>
    <description>occurrence of IC acquired weakness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">356</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A: treated with intravenous hydrocortisone in addition to standard therapy (= treatment group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group B: IV treatment with NaCL 0.9% in addition to standard therapy (= placebo group)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>IV bolus of 100 mg hydrocortisone in 50ml NaCl 0.9% (sodium chloride); followed by continuous IV infusion of 200 mg hydrocortisone in 50 ml NaCl 0.9% at a rate of 2 ml/h until the start of day 4.Reduction of infusion rate with 0.5 ml/h/day.</description>
    <arm_group_label>group A</arm_group_label>
    <other_name>solucortef</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCL 0.9%</intervention_name>
    <description>IV bolus of 50 ml NaCL 0.9%; followed by continuous IV infusion of NaCL 0.9%</description>
    <arm_group_label>group B</arm_group_label>
    <other_name>sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with known or recently diagnosed cirrhosis who

               1. are admitted to the ICU because of persistent hypotension or

               2. develop persistent hypotension while admitted to the ICU,

        secondary to proven or suspected infection, in both cases despite adequate fluid
        resuscitation and with persistent need for low-dose norepinephrine to maintain a mean
        arterial blood pressure &gt; 60 mmHg or &gt; 65 mmHg if accompanied by signs of hypoperfusion,
        are eligible for study entry. The diagnosis of cirrhosis is preferably made by histology or
        based on imaging and laboratory findings.

        Exclusion Criteria:

          -  Age &lt; 18 or ≥ 80 years

          -  Patients receiving any vasopressor medication for more than 24 h prior to
             administration of study drug. Terlipressin initiated for treatment of hepatorenal
             syndrome or variceal bleeding is allowed

          -  Patients with known hypoadrenalism

          -  Active GI bleeding (unless controlled for &gt;72 hours) or hemorrhagic shock.

          -  Cardiogenic shock or severe cardiac dysfunction (CI &lt;2 l/min/ m2)

          -  Active uncontrolled hepatitis B infection

          -  HIV infection

          -  Evidence of current malignancy (except hepatocellular carcinoma within transplant
             criteria or non-melanocytic skin cancer)

          -  Therapy with any corticosteroid (oral or intravenous) in the last 3 months

          -  Patients who received etomidate within the past 3 days

          -  Severe acute alcoholic hepatitis (biopsy proven)

          -  Chronic hemodialysis

          -  Severe chronic heart disease (NYHA class III or IV)

          -  Severe chronic obstructive pulmonary disease (GOLD III or IV)

          -  Severe psychiatric disorder

          -  Child-Pugh score C14 -15

          -  SOFA score &gt; 16 points at inclusion

          -  Pregnant or breastfeeding women

          -  Contraindications for systemic steroids

          -  Refusal to consent

          -  Patients who cannot provide prior informed consent and when there is documented
             evidence that the patient has no legal surrogate decision maker and it appears
             unlikely that the patient will regain consciousness or sufficient ability to provide
             delayed informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Meersseman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Wilmer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Fernandez, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hosp Clinic, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe Meersseman, MD</last_name>
    <phone>+32 16341335</phone>
    <email>philippe.meersseman@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexander Wilmer, MD, PhD</last_name>
    <phone>+32 16 344275</phone>
    <email>alexander.wilmer@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Meersseman</last_name>
      <phone>+3216341335</phone>
      <email>philippe.meersseman@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Alexander Wilmer</last_name>
      <email>alexander.wilmer@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Philippe Meersseman</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Wilmer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Hoste</last_name>
      <email>eric.hoste@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Eric Hoste</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hans Van Vlierberghe</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute for Clinical and Experimental Medicine</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Sperl</last_name>
      <email>jan.sperl@ikem.cz</email>
    </contact>
    <investigator>
      <last_name>Jan Sperl</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sona Frankova</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva Kieslichova</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aarhus Iniversity Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henning Grønbæk</last_name>
      <email>henning.gronbaek@aarhus.rm.dk</email>
    </contact>
    <investigator>
      <last_name>Henning Grønbæk</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Niels Aagaard</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fin S Larsen</last_name>
      <email>fin.stolze.larsen@rh.regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Fin S Larsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valentin Fuhrmann</last_name>
      <email>v.fuhrmann@uke.de</email>
    </contact>
    <investigator>
      <last_name>Valentin Fuhrmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Horvatits</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Benten</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Giovanni Battista Hospital</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Ottobrelli</last_name>
      <email>aottobrelli@cittadellasalute.to.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Ottobrelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Davide Stradella</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Fernandez</last_name>
      <email>JFDEZ@clinic.ub.es</email>
    </contact>
    <contact_backup>
      <last_name>Rita Garcia</last_name>
      <email>RIGARCIA@clinic.ub.es</email>
    </contact_backup>
    <investigator>
      <last_name>Javier Fernandez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Banares</last_name>
      <email>rbanares@telefonica.net</email>
    </contact>
    <investigator>
      <last_name>Rafael Banares</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agustin Albillos</last_name>
      <email>agustin.albillos@uah.es</email>
    </contact>
    <investigator>
      <last_name>Agustin Albillos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>William Bernal</last_name>
      <email>william.bernal@nhs.net</email>
    </contact>
    <investigator>
      <last_name>William Bernal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Acevedo, PI</last_name>
      <email>jacevedo@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Victoria Yates, Nat. Coordin</last_name>
      <email>victoriayates@nhs.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2015</study_first_submitted>
  <study_first_submitted_qc>November 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2015</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cirrhosis</keyword>
  <keyword>liver</keyword>
  <keyword>corticosteroids</keyword>
  <keyword>hypotension</keyword>
  <keyword>sepsis</keyword>
  <keyword>cortisol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

